infertility: update on evaluation & treatment latasha b. craig, m.d. assistant professor...

63
INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma Health Sciences Center

Upload: junior-bates

Post on 15-Jan-2016

223 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

INFERTILITY: Update on Evaluation &

Treatment

LaTasha B. Craig, M.D.Assistant Professor

Division of Reproductive EndocrinologyUniversity of Oklahoma Health Sciences

Center

Page 2: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Objectives Understand the different causes of infertility and

the specific evaluations to diagnose each cause.

Comprehend the available infertility treatment options including their chance of pregnancy, complications and chance of multiple gestations.

Have an understanding of the process and success of in vitro fertilization (IVF) & the concerns for long term outcomes of children born from IVF.

Page 3: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Speaker Disclosure I have no financial

relationships or affiliations to disclose.

Many of the medications used in in vitro fertilization are not FDA approved for this indication.

Page 4: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Considerations Pre-Pregnancy Nutritional issues Medical conditions Medications Immunization history Family history and genetic risk Tobacco, alcohol, caffeine & substance use Occupational & environmental exposures

Page 5: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

How to time conception Cycle Day (CD) 1 is

the first day of full-flow bleeding

Have intercourse every 2 -3 days (especially between CD 10-20)

Avoid most over-the-counter lubricants

Things to consider: Ovulation Predictor Kits Basal Body

Temperature Charting

Things to avoid: Over the counter

fertility tests Salivary hormone tests Hormonal supplements

Page 6: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Basal Body Temperature Monitoring

Newill RG, Katz M. The basal body temperature chart in artificial insemination by donor pregnancy cycles. Fertil Steril 1982 Oct;38(4):431-8

Page 7: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Ovulation Predictor Kits:

Page 8: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

What to Expect--Fecundability: Cumulative pregnancy rate

0102030405060708090

100

% Pregnant

3 mos 6 mos 1 year 2 years

Duration of exposure

Guttmacher, 1956

Page 9: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Definition of Infertility

Failure to conceive after 1 year of unprotected intercourse

The exception: For women ≥ 35 years old, 6 months unprotected intercourse without conception

Page 10: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Infertility Incidence Diagnostic

evaluation Treatment

options

Page 11: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Historical perspective on fertility In 1790 U.S. census, birth

rate was 55 per 1000 population with avg. of 8 births per woman

1995 National Survey of Family Growth (NSGF), birth rate of 15.5 per 1000, with avg. births of 1.2 per woman

Popular explanations for declining U.S. fertility

Changing roles & aspirations for women

Postponement of marriage Delayed age of

childbearing Increasing use of

contraception Liberalized abortion

Speroff. Clinical Gynecologic Endocrinology & Infertility. Sixth edition.

Page 12: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Components of Normal Fertility

Page 13: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Etiologies by percent in couples presenting for infertility

Page 14: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Male Infertility Evaluation: Semen Analysis

Volume 2.0 - 5.0 mL

pH >7.2

Concentration >20 million / mL

Total sperm number >40 million / ejaculate

Motility >50%

Forward progression >2 (scale 0-4)

Sperm morphology >30% normal (WHO 1992)

>14% normal (WHO 1999)

Page 15: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Female Infertility Evaluation: Tubal/Pelvic Factor

Page 16: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Hysterosalpingogram (HSG)

Normal Bilateral Blocked Tubes

Page 17: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Female Infertility Evaluation:

Confirm ovulation by History of regular cycles Symptoms of ovulation Ovulation predictor kits Basal body temperature Progesterone level around

CD 21 Ultrasound monitoring

Ovulation Dysfunction

Page 18: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Ovarian Aging: Depletion of primordial follicles

Picture from: http://embryology.med.unsw.edu.au/Notes/im

ages/week1/ovary/oocytenumber.jpg

Page 19: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Ten various populations ranging from 17th to mid-20th century.

Marital fertility rates by 5-year age groups

Menken J, Trussel J, Larsen U. Age and infertility. Science 1986;23:1389-1394.

Page 20: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

2009 Assisted Reproductive Technology Success Rates, National Summary and Fertility Clinic Reports (CDC)

Page 21: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

2009 Assisted Reproductive Technology Success Rates, National Summary and Fertility Clinic Reports (CDC)

Page 22: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Female age Cycle day 3

FSH & estradiol

AMH level Vaginal

ultrasound for antral follicles

Assessment of Ovarian Reserve

Page 23: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Treatment Options Directly correct a problem if possible (i.e.

thyroid tx, Bromocriptine, weight loss, etc) If unable to correct the underlying

problem, then use empiric treatment: Intrauterine insemination (IUI or AI) Ovulation Induction Assisted Reproductive Technology (i.e. in vitro

fertilization – IVF)

Page 24: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Treatment Options: Intrauterine Insemination (IUI)

Picture from Familydoctor.co.uk

Page 25: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Treatment Options: Ovulation Induction

By mouth: Clomiphene (Clomid) or Letrozole (Femara) Pregnancy rate is 10% per cycle (higher in

PCOS patients). Risk of twins 8-10% and risk of triplets or

more less than 1% Side Effects: hot flushes, nausea,

headaches, mood swings, blurred vision, thin uterine lining, poor cervical mucus.

Page 26: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Injectable medications: Gonadotropins (FSH, LH) Pregnancy rate is 10-20% each cycle

(controversial) Risk of twins up to 30% and risk of triplets

or more 5-10% Side effects of medication are minimal

because it is a natural hormone. Chance of overstimulation and canceling cycle.

Treatment Options: Ovulation Induction

Page 27: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Gonadotropins

Page 28: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Polycystic Ovarian Syndrome (PCOS)

Page 29: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Adjunct to Ovulation Induction in PCOS 1500-2000 mg/ day May not be covered by

insurance in non-diabetics Re-introduce clomid

Metformin

Ovarian Drilling Ovulation rates, 50-80% Adhesion risk, 10-15% Longest study, 5 year follow-up1

(206 patients) 70% Pregnancy rate (1/2 treated) 50% Live birth rate

1 Naether OG et al., Human Reprod 9(12):2342-9, 1994

Page 30: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Which of the following do you believe: All patients with PCOS should be on

metformin All PCOS patients wanting to conceive

should be on metformin Metformin is only indicated if a patient has

diabetes or impaired glucose tolerance.

Page 31: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Metformin in PCOS

0

10

20

30

40

50

60

70

80

90

placebo placebo+CC metformin met+CC

ovulation

Nestler JE, et al. NEJM 338(26):1876-80, 1998

Page 32: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Metformin in PCOS

BeforeBefore AfterAfter

Insulin Insulin microU/mLmicroU/mL

26 26 2222

TestosteroneTestosterone

ng/dLng/dL

6161 4747

Glueck CJ, et al. Metabolism Apr;48(4):511-9, 1999

Page 33: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Is metformin more effective than clomid?

Randomized controlled trial of metformin 850 mg bid vs. clomiphene citrate 150 mg qd cycle days 5-9

Cumulative ovulation rate not different (63 vs. 67%)

Pregnancy rate/cycle = 15.1% metformin; 7.2% clomiphene (p = 0.009)

Palomba et al. JCEM 90(7): 4068-74, 2005Palomba et al. JCEM 90(7): 4068-74, 2005

Page 34: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Does metformin decrease the spontaneous miscarriage rate in PCOS?

Randomized controlled trial of metformin 850 mg bid vs. clomiphene citrate 150 mg qd cycle days 5-9

Metformin group miscarriage = 3/31 (9.7%) Clomid group miscarriage = 6/16 (37.5%) P = 0.045

Palomba et al. JCEM 90(7): 4068-74, 2005Palomba et al. JCEM 90(7): 4068-74, 2005

Page 35: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Is metformin more effective than clomid?

Legro et al. NEJM 356,6: 551-66, 2007Legro et al. NEJM 356,6: 551-66, 2007

Metformin + Metformin + placeboplacebo

Clomid + placeboClomid + placebo Metformin + Metformin + ClomidClomid

nn 208208 209209 209209

% of cycles that % of cycles that were ovulatorywere ovulatory 29%29% 49%49% 60%60%

% pregnant/ % pregnant/ ovulatory cycleovulatory cycle 8.4%8.4% 13.4%13.4% 13.7%13.7%

% live birth% live birth7.2%7.2% 22.5%22.5% 26.8%26.8%

Page 36: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

What if all the tests are normal?

Unexplained Infertility ~10% of couples

Page 37: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Guzick et al. Efficacy of treatment for unexplained infertility.Fertil Steril. 1998 Aug;70(2):207-13.)

Treatment % preg

No treatment 2.6%

IUI 3.8%

Clomiphene 5.6%

Clomiphene+IUI 8.3%

Gonadotropins 7.7%

Gonadotropins+IUI 17.1%

IVFIVF 20.7%20.7%

Treatment Options: Unexplained Infertility

See next slide

Page 38: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

OU Reproductive Medicine IVF Statistics

( (Delivered per embryo transfer in 2010)

Age group (years)

% P

reg

nan

t o

r D

eliv

ered

* A comparison of clinic success rates may not be meaningful because patient medical characteristics, treatment approaches and entrance criteria for ART may vary from clinic to clinic.

Page 39: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Treatment Options: In Vitro Fertilization (IVF) & ART

Blocked tubes Severe male factor Unexplained infertility Endometriosis/peritoneal factor infertility Failure to conceive with less aggressive

treatment Ovarian failure/ ovarian reserve (donor eggs)

Page 40: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

MDsMDs

LabLab• Embryology• Embryology• Andrology• Andrology• Endocrine• Endocrine

NursingNursingStaffStaff

Office &Office & Clinic Clinic Staff Staff

ART Team

Page 41: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Assisted Reproductive Technology—ART

1978/1981 In vitro fertilization—IVF 1984 Donor oocyte (egg) cycle 1985 Cryopreserved Embryo Transfer 1990 Preimplantation Genetic Diagnosis—PGD 1992 Intracytoplasmic Sperm Injection—ICSI

As of 2004, more than 1 million children born worldwide as a result of ART

Page 42: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

IVFLuteal Leuprolide Protocol

OCPs14-28 days

Lupron24-30 days

Gonadotropins8-12 days

hCG

Retrieval

Transfer

2days

3-6days

Page 43: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Monitoring FolliclesIVF Ultrasound

Page 44: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Sonographic Egg Recovery

Page 45: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Sonographic Egg Recovery

Page 46: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Intracytoplasmic sperm injection—ICSI

Discovered “by accident” in 1991 in a Belgian IVF lab

Successfully treats almost all forms of severe male factor infertility

Page 47: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

ICSI

Page 48: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Timing of Embryo Transfer

Day 3 Embryo Transfer

Day 5–6 Embryo Transfer “Blastocyst Transfer”

Veeck LL, Zaninovic N. An Atlas of Human Blastocysts. 1st ed. New York: Parthenon Publishing, 2003;118.

Page 49: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Embryo Transfer

Page 50: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Loading Catheter

Page 51: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Embryo Transfer

Page 52: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Outcomes—Children

Page 53: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Children of ARTPossible Risks

Multiple pregnancy Low birth weight Congenital anomalies Transmission of parental genetic

abnormalities (e.g., male factor) Imprinting defects Developmental abnormalities

Page 54: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

OCTOMOM: Nadya Suleman

Page 55: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

2009 Assisted Reproductive Technology Success Rates, National Summary and Fertility Clinic Reports (CDC)

Page 56: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Octomom’s Clinic: West Coast IVF

Clinic, Inc.In 2007, 19 patients < 35 years old

2 became pregnant1 delivered

Average # embryos transferred: 4.1

Page 57: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Preimplantation Genetic Testing Preimplantation Genetic Screening (PGS)

Advanced reproductive age Recurrent pregnancy loss Multiple failed IVF cycles

Preimplantation Genetic Diagnosis (PGD) Sex-linked disorders (FISH or PCR) Single gene disease

Autosomal recessive (PCR) Autosomal dominant (PCR)

Translocations (FISH)

Page 58: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

A

FE

C D

B

An Atlas of Preimplantation Genetic Diagnosis pg 91

Page 59: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

The Technology: PGS and Chromosome Translocations

Fluorescent In-Situ Hybridization (FISH)

Alternatives in the near future:Comparative Genomic Hybridization (CGH)

Multiple Displacement Amplification

Gene Chips

Pyro Sequencing

Page 60: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Trisomy 21 Embryo

Chromosome 21

Chromosome 21

Chromosome 21

An Atlas of Preimplantation Genetic Diagnosis pg 114

Page 61: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

When should you refer your patient:

You’ve been trying to conceive for > 1year

You do not have regular periods

You are > 35 years old You have a history of

sexually transmitted diseases (i.e. chlamydia)

Page 62: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

Conclusions Basic Infertility Evaluation Understand the treatment options Understand the complications of treatments

We do not know all of the long-term effects of ART because it is still a relatively young field of study.

Page 63: INFERTILITY: Update on Evaluation & Treatment LaTasha B. Craig, M.D. Assistant Professor Division of Reproductive Endocrinology University of Oklahoma

THANK YOU

QUESTIONS?

LaTasha B Craig, MD

University of Oklahoma Health Sciences Center

Section of Reproductive Endocrinology & Infertility

Department of Obstetrics & Gynecology

www.OUInfertility.com